drugset / Trial / NCT00038220

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

NCT00038220

Phase 2 Completed 40 enrolled Abbott
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the growth of HIV in patients infected with the virus.

Timeline

Start
2000-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified
Subject Lamivudine Other / unclassified
Subject Lopinavir/ritonavir Unknown
Subject Tenofovir disoproxil fumarate Small molecule